Skip to main content
OpenTrials
Completed

NCT Number: NCT02297958

Impact of Fas/FasL in Chemotherapy Response in Epithelial Ovarian Carcinoma

Ovarian carcinoma has poor prognosis and new therapeutic strategies are required. Many patients with ovarian carcinoma showed resistance to chemotherapy. Cleaved FasL is known for induced atypical response when is binding to Fas such as avoiding apoptosis and inducing cell motility.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Ovarian Carcinoma Adnexal Diseases Endocrine Gland Neoplasms Endocrine System Diseases Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genital Diseases Genital Diseases, Female Genital Neoplasms, Female Gonadal Disorders Neoplasms Neoplasms by Site Ovarian Diseases Ovarian Neoplasms Urogenital Diseases Urogenital Neoplasms

Age range

18 year and older

Sex eligibility

Female

Study type

Observational

Primary location

Service de Gynécologie

Rennes, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Pre-Inclusion Criteria:

  • Patient with suspicious ovarian carcinoma using clinical data, biological data (ca125) and radiological data (CT)

Inclusion criteria

  • Pathological ovarian carcinoma diagnosed at pathological analysis after surgery.
  • Neo adjuvant chemotherapy

Exclusion criteria

  • no neo-adjuvant chemotherapy
  • no ovarian carcinoma at final pathological analysis
  • less than 18 years old.

Treatment and study plan

Primary outcomes

  1. Correlation between cleaved FasL level ans neoadjuvant chemotherapy tumor response

    Time frame: surgery

    Main outcome is cleaved FasL level and correlation with neoadjuvant chemotherapy tumor response, evaluated during surgery.

Secondary outcomes

  1. Identification of tumoral T cells

    Time frame: surgery

    Identification of tumoral T cells with FACS analysis of dissociated tumor. Different T cells will be studies: Treg/Th17/Th1/Th2 using antibodies against: CD45/CD3/CD4/CD25/FOXP3 (Treg), CD45/CD3/CD4/IL17A (Th17), CD45/CD3/CD4/CD8/IL4/INF (TCD8 and LTCD4 Th1 et Th2).

  2. Disease Free Survival rate

    Time frame: 18 months after surgery

  3. Overall survival rate

    Time frame: 18 months after surgery

Sponsors and collaborators

Lead sponsor

Rennes University Hospital

Other

Registry information

Acronym: IFFaLCCO

Important dates

Study start
2015
Primary completion
2019
Study completion
2019
First posted
Nov 21, 2014
Registry last updated
Aug 31, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.